Our Continuing Medical Education (CME) Empowerment Series aims to provide effective platforms for medical professionals to acquire, share, and exchange knowledge from clinical experience.
The year's CME presentations bring the latest updates on cancer management and offer insights on our multi-disciplinary approach to the treatment of major and rare cancers to doctors and specialists. New services such as Chimeric Antigen Receptor (CAR) T-cell Therapy and Proton Therapy and their impact on delivering better clinical outcomes for patients would also be covered.
View our key CME sessions here.
Collapse All
Expand All

Parkway Cancer Centre (PCC) Tumour Board is a multidisciplinary discussion platform where challenging oncology cases are presented for discussion. Following each case presentation, we have a live interactive review of the radiology images and pathology slides by the respective experts, followed by an in-depth discourse of each case. To enhance the learning experience for all participants, we incorporate a short commentary on a particular interesting aspect of each case to be given by the presenters.

HER2 overexpressed breast cancer tends to affect younger patients compared to HER2 negative breast cancer. Fortunately, overall survival and cure have increased in the last 20 years due to the expansion of therapeutic options. For patients with Low volume disease the key is to find treatments that are compatible with long term preservation of function and quality of life.

We will provide two cases to illustrate the different options of treatment with radiation chemotherapy and localised treatment with discussions from a panel of colleagues.

  • Case 1- management of soft tissue only failure
  • Case 2- management of brain only failure

Speakers

dr see hui ti

Dr See Hui Ti

Senior Consultant
Medical Oncology
Parkway Cancer Centre

professor sherene loi

Professor Sherene Loi

Senior Consultant
Medical Oncology
Peter MacCallum Cancer Centre

dr ivan tham

Dr Ivan Tham

Senior Consultant
Radiation Oncology
Parkway Cancer Centre

dr Andrew clayton lee

Dr Andrew Clayton Lee

General Surgeon and Oncoplastic Breast Surgeon
Gleneagles Hospital

dr peter goh

Dr Peter Goh

Senior Consultant and Group Medical Director
Vascular and Interventional Radiologist
Department of Radiology
Mount Elizabeth Hospital

DATE

Thursday, 18 August 2022

TIME

5PM – 6:30PM SGT

PLATFORM

Online Webinar

CLICK HERE TO REGISTER

Rare cancers are variably defined as having an incidence rate less than 5-15 per 100,000 persons per year. Collectively, up to a quarter of cancers may fall into the umbrella of rare cancers.

Depending on genetic profiles, ethnicity, geography, and other modifiable risk factors, the types of rare cancers encountered vary significantly from place to place. Due to small patient numbers, robust clinical data guiding care is oftentimes absent.

However, the advent of routine tumour molecular testing and its wide-spread adoption in clinical use has opened up an entire treatment paradigm for our patients. In this lecture, we aim to shine the spotlight on rare cancers, and share the opportunities and challenges that lie ahead in these diseases.

 

  1. Highlight the various types of rare cancers
  2. Highlight the challenges associated with management of patients with these rare cancers.
  3. Discuss the challenges and opportunities in studying these rare cancers

 

Speaker

dr richard quek

Dr Richard Quek

Senior Consultant
Medical Oncology
Parkway Cancer Centre

DATE

Thursday, 28 July 2022

TIME

1PM – 2PM SGT

PLATFORM

Online Webinar

CLICK HERE TO REGISTER

Parkway Cancer Centre (PCC) Tumour Board is a multi-disciplinary discussion platform where challenging oncology cases are presented for discussion. Following each case presentation, we have a live interactive review of the radiology images and pathology slides by the respective experts, followed by an in-depth discourse of each case. To enhance the learning experience for all participants, we incorporate a short commentary on a particular interesting aspect of each case to be given by the presenters.

In this coming Tumour Board, we will cover a few cases of challenging common blood cancer. We will present/ discuss :

 

  • A case of leukemia with uncommon presentation with challenging management.
  • A case of refractory lymphoma successfully treated with CAR T-cells.
  • A case with CA colon and hemolytic anaemia.

 

Speakers

dr lee yuh shan

Dr Lee Yuh Shan

Senior Consultant
Haematology
Parkway Cancer Centre

dr colin phipps diong

Dr Colin Phipps Diong

Senior Consultant
Haematology
Parkway Cancer Centre

dr dawn mya

Dr Dawn Mya

Senior Consultant
Haematology
Parkway Cancer Centre

dr roland chong

Dr Roland Chong

Senior Consultant
Gastroenterologist
Gleneagles Hospital

dr peter goh

Dr Peter Goh

Senior Consultant and Group Medical Director
Vascular and Interventional Radiologist
Department of Radiology
Mount Elizabeth Hospital

dr brendan pang

Dr Brendan Pang

Consultant Pathologist
ParkwayHealth Laboratory Services

DATE

Thursday, 21 July 2022

TIME

5PM – 6:30PM SGT

PLATFORM

Online Webinar

CLICK HERE TO REGISTER

Prostate cancer is the third most common cancer among Singaporean men. The number of prostate cancer cases in Singapore has doubled in the last two decades. It is estimated that 30% of prostate cancer patients present at stage 4, typically with cancer having spread to bones. The historical standard treatment of metastatic castration-sensitive prostate cancer is androgen deprivation therapy (ADT) alone. Even though the majority of patients respond to ADT, all patients will develop further cancer progression. Recent trials have shown that early treatment intensification strategy by adding chemotherapy and/or novel hormonal agent to ADT significantly improves overall survival.

Speaker

dr wong siew wei

Dr Wong Siew Wei

Senior Consultant
Medical Oncology
Parkway Cancer Centre

DATE

Thursday, 26 May 2022

TIME

1PM – 2PM SGT

PLATFORM

Online Webinar

CLICK HERE TO REGISTER

Parkway Cancer Centre (PCC) Tumour Board is a multi-disciplinary discussion platform where challenging oncology cases are presented for discussion. Following each case presentation, we have a live interactive review of the radiology images and pathology slides by the respective experts, followed by an in-depth discourse of each case. To enhance the learning experience for all participants, we incorporate a short commentary on a particular interesting aspect of each case to be given by the presenters.

In this upcoming tumour board, a series of 5 interesting, challenging, difficult and unusual cases will be discussed:

  1. Merkel cell carcinoma I
  2. Merkel cell carcinoma II
  3. MPNST (malignant peripheral nerve sheath tumour)
  4. Cardiac sarcoma
  5. Thyroid cancer
  6. Speaker

    dr richard quek

    Dr Richard Quek

    Senior Consultant
    Medical Oncology
    Parkway Cancer Centre

    dr tay hin ngan

    >Dr Tay Hin Ngan

    Senior Consultant
    Otolaryngologist/Head & Neck Surgeon
    Mount Elizabeth Hospital

    dr lim yeong phang

    Dr Lim Yeong Phang

    Senior Consultant
    Cardiovascular and Thoracic Surgeon
    Mount Elizabeth Novena Hospital

    dr tan ngian chye

    Dr Tan Ngian Chye

    Senior Consultant
    Head & Neck and General Surgeon
    Mount Elizabeth Novena Hospital

    dr gurpal singh

    Dr Gurpal Singh

    Senior Consultant
    Orthopaedic Surgeon
    Mount Elizabeth Novena Hospital

    dr colin tan

    Dr Colin Tan

    Consultant
    Nuclear Medicine Physician and Radiologist
    Parkway Hospitals

    dr peter goh

    Dr Peter Goh

    Senior Consultant and Group Medical Director
    Vascular and Interventional Radiologist
    Department of Radiology
    Mount Elizabeth Hospital

    dr brendan pang

    Dr Brendan Pang

    Consultant Pathologist
    ParkwayHealth Laboratory Services

DATE

Thursday, 19 May 2022

TIME

5PM – 6.30PM SGT

PLATFORM

Online Webinar

CLICK HERE TO REGISTER

Parkway Cancer Centre (PCC) Tumour Board is a multi-disciplinary discussion platform where challenging oncology cases are presented for discussion. Following each case presentation, we have a live interactive review of the radiology images and pathology slides by the respective experts, followed by an in-depth discourse of each case. To enhance the learning experience for all participants, we incorporate a short commentary on a particular interesting aspect of each case to be given by the presenters.

In this upcoming tumour board, we will cover locally advanced and metastatic gastroenteropancreatic neuroendocrine tumours(GEP-NET):

  1. Case presentation of an Appendiceal carcinoid case by Dr Quah Hak Mien
  2. Discussion on pathology of neuroendocrine tumours and discussion on appendiceal carcinoid, indications for hemicolectomy and adjuvant treatment.
  3. Case presentation of metastatic GEP-NET cases by Dr Foo Kian Fong.
  4. Discussion on management of advanced GEP NET
  5. Discussion on emerging use of peptide related radiotherapy (PRRT) in treatment of GEP NET
  6. Speaker

    dr foo kian fong

    Dr Foo Kian Fong

    Senior Consultant
    Medical Oncology
    Parkway Cancer Centre

    dr zee ying kiat

    Dr Zee Ying Kiat

    Senior Consultant
    Medical Oncology
    Parkway Cancer Centre

    dr quah hak mien

    Dr Quah Hak Mien

    Consultant Colorectal and General Surgeon
    Gleneagles Medical Centre

    dr lau kui hin

    Dr Lau Kui Hin

    Medical Director & Senior Consultant Surgeon
    Mount Elizabeth Hospital

    dr colin tan

    Dr Colin Tan

    Consultant
    Nuclear Medicine Physician and Radiologist

    dr brendan pang

    Dr Brendan Pang

    Consultant Pathologist
    ParkwayHealth Laboratory Services

    dr peter goh

    Dr Peter Goh

    Senior Consultant and Group Medical Director
    Vascular and Interventional Radiologist
    Department of Radiology
    Mount Elizabeth Hospital

DATE

Thursday, 21 April 2022

TIME

5PM – 6.30PM SGT

PLATFORM

Online Webinar

CLICK HERE TO REGISTER

Parkway Cancer Centre (PCC) Tumour Board is a multi-disciplinary discussion platform where challenging oncology cases are presented for discussion. Following each case presentation, we have a live interactive review of the radiology images and pathology slides by the respective experts, followed by an in-depth discourse of each case. To enhance the learning experience for all participants, we incorporate a short commentary on a particular interesting aspect of each case to be given by the presenters.

In this upcoming tumour board, we focus on the topic of high-risk muscle-invasive bladder cancer and metastatic bladder cancer.

  • Case presentation of a muscle-invasive bladder cancer case by Dr Poh Beow Kiong
  • Discussion on challenges of clinical staging in muscle invasive bladder cancer, indications and benefit of multimodality treatment
  • Case presentation of a metastatic bladder cancer by Dr Lee Fang Jann
  • Discussion on clinical factors to consider in treatment selection in first line metastatic bladder cancer and role of maintenance immunotherapy
  • Discussion on emerging new drugs in metastatic bladder cancer

 

Speakers

dr richard quek

Dr Richard Quek

Senior Consultant
Medical Oncology
Parkway Cancer Centre

dr wong siew wei

Dr Wong Siew Wei

Senior Consultant
Medical Oncology
Parkway Cancer Centre

dr peter goh

Dr Peter Goh

Senior Consultant and Group Medical Director
Vascular and Interventional Radiologist
Department of Radiology
Mount Elizabeth Hospital

dr brendan pang

Dr Brendan Pang

Consultant Pathologist
ParkwayHealth Laboratory Services

dr poh beow kiong

Dr Poh Beow Kiong

Urologist
Mount Elizabeth Hospital

dr lee fang jann

Dr Lee Fang Jann

Consultant Urologist
URODOC

DATE

Thursday, 31 March 2022

TIME

5PM – 6.30PM SGT

PLATFORM

Online Webinar

CLICK HERE TO REGISTER

Over the last 15 years The Cancer Genome Atlas Program, a joint effort between the National Cancer Institute and The National Human Genome Research Institute, have characterized over 20,000 primary cancers and their outcomes. That has translated to changes to guidelines as to how we recommend treatment to our patients with endometrial cancer. Histologically bizarre subtypes that had traditionally been associated with potentially unfavourable characteristics can be subtypes to a molecularly favourable pattern though next generation sequencing and histological correlation. Additional treatments such as radiation or chemotherapy may in turn be non-beneficial to patients with such tumours. 

How does that change the way we prognosticate cancer and counsel patients for treatment before surgery and after surgery?

Join Dr See Hui Ti, Dr Chia Yin Nin, Dr Lee Kuo Ann and Ms Tay Ru Jin as they will share scenarios to illustrate a paradigm shift in management of patients with early endometrial cancer. 

Speakers

dr see hui ti

Dr See Hui Ti

Senior Consultant
Medical Oncology
Parkway Cancer Centre

dr chia yin nin

Dr Chia Yin Nin

Gynaecological Oncologist
Obstetrics & Gynaecology
Gynaecology & Oncology Specialists

dr lee kuo ann

Dr Lee Kuo Ann

Senior Consultant
Radiation Oncology
Parkway Cancer Centre

ms tay ru jin

Ms Tay Ru Jin

Lead Genetic Counsellor
Lucence

DATE

Thursday, 24 March 2022

TIME

1PM – 2PM SGT

PLATFORM

Online Webinar

CLICK HERE TO REGISTER

Parkway Cancer Centre (PCC) Tumour Board is a multi-disciplinary discussion platform where unusual or challenging oncology cases are presented for discussion.

This tumour board session will focus on lymphoma and acute lymphoblastic lymphoma cases including those that are amenable to anti-CD19 chimeric antigen receptor CAR T-cell therapy.

In addition to our own local cases, Prof Kim of Samsung Medical Center will also provide insight and their experience with the use of the commercial CAR T-cell product.

Speakers

dr colin phipps diong

Dr Colin Phipps Diong

Senior Consultant
Haematology
Parkway Cancer Centre

dr peter goh

Dr Peter Goh

Senior Consultant and Clinical Director
Vascular and Interventional Radiologist
Department of Radiology
Mount Elizabeth Hospital

prof kim seok jin

Prof Kim Seok Jin

Haematologist
Division of Haematology-Oncology Samsung Medical Centre
Sungkyunkwan University School of Medicine
Seoul, Korea

DATE

Thursday, 24 February 2022

TIME

5PM – 6.30PM SGT

PLATFORM

Online Webinar

CLICK HERE TO REGISTER

Colorectal cancer is the most commonly diagnosed cancer in Singapore. Fortunately, it is preventable through basic dietary and lifestyle changes. Screening is proven to reduce colorectal cancer-specific mortality, and may also serve as a form of cancer prevention. When colorectal cancer is diagnosed, accurate staging is essential prior to treatment.

While many patients diagnosed with colorectal cancer are treated with curative intent, patients with advanced incurable disease should still be considered for treatment with the aim of meaningfully prolonging life. Treatment modalities include surgery, chemotherapy, targeted therapy, immunotherapy and radiotherapy. The presentation focus will be on indications for specialist referral and guidelines for post-treatment follow-up.

Speakers

dr zee ying kiat

Dr Zee Ying Kiat

Senior Consultant
Medical Oncology
Parkway Cancer Centre

dr eugene yeo

Dr Eugene Yeo

Senior Consultant
Colorectal & General Surgeon
Mount Elizabeth Hospital

DATE

Saturday, 19 February 2022

TIME

2PM – 3PM SGT

PLATFORM

Online Webinar

CLICK HERE TO REGISTER

(Registration closes on 18 February 2022.)

Collapse All
Expand All